title: Dengue: an update on treatment options.
abstract: Dengue is the most important mosquito-borne viral pathogen globally, with approximately 100 million cases of acute dengue annually. Infection can result in severe, life-threatening disease. Currently, there is no effective vaccine or licensed antiviral. Management is primarily supportive with fluids. Direct antiviral therapies that reduce dengue severity could be useful although these would need to inhibit all four viral serotypes effectively. This review focuses on the interventions that currently considered the gold standard in case management as well as exploratory therapies that have been studied in clinical trials. Although antiviral drug and therapeutic antibodies for dengue remain a work in progress, these studies have produced some promising results and may have the potential to be future drugs.
authors.affiliation: Department of Infectious Diseases, Singapore General Hospital, Singapore.|Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, 8 College Road, 169857, Singapore.
authors.forename: Candice Y Y
authors.initials: CY
authors.lastname: Chan
authors.forename: Eng Eong
authors.initials: EE
authors.lastname: Ooi
mesh_terms: D002986:Clinical Trials as Topic; D003715:Dengue / Q000628:therapy*; D055808:Drug Discovery / Q000639:trends; D005440:Fluid Therapy / Q000379:methods*; D006801:Humans
keywords: antiviral drug; dengue; flavivirus; therapeutic monoclonal antibodies